Gallic Acid

Gallic Acid

SCHEMBL702574

O=C([O-])c1cc(O)c(O)c(O)c1.O=C([O-])c1cc(O)c(O)c(O)c1.O=C([O-])c1cc(O)c(O)c(O)c1.[Y+3]

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.56
LMNA P02545 3/20 0.56
TDP1 Q9NUW8 3/20 0.56
ALDH1A1 P00352 2/20 0.56
MAPT P10636 2/20 0.56
FUT7 Q11130 2/20 0.56
CA1 P00915 2/20 0.56
CA2 P00918 2/20 0.56
CA12 O43570 1/20 0.56
TP53 P04637 1/20 0.56
CA3 P07451 1/20 0.56
SELL P14151 1/20 0.56
HPGD P15428 1/20 0.56
SELP P16109 1/20 0.56
FUT4 P22083 1/20 0.56
CA4 P22748 1/20 0.56
CA6 P23280 1/20 0.56
DPP4 P27487 1/20 0.56
MAPK1 P28482 1/20 0.56
CA5A P35218 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gallic Acid SCHEMBL9398057 0.97 KDM4E (0.54) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL27958245 0.97 KDM4E (0.54) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL28654164 0.97 KDM4E (0.59) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL29155376 0.95 KDM4E (0.52) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL9185407 0.95 KDM4E (0.56) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL2522449 0.95 KDM4E (0.56) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL11242131 0.95 KDM4E (0.56) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL21273260 0.95 KDM4E (0.56) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL21273262 0.95 KDM4E (0.56) KDM4ELMNATDP1ALDH1A1MAPT
Gallic Acid SCHEMBL3630313 0.95 KDM4E (0.56) KDM4ELMNATDP1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12539278-B2 Nanocomposite particle and uses thereof ACADEMIA SINICA (TW) 2026-02-03 US claimed
US-12515067-B2 Non-invasive systems and methods for selective activation of photoreactive responses IMMUNOLIGHT, LLC (US) 2026-01-06 US claimed
CN-119352160-B Rare earth doped yttrium gallate laser material and preparation method and application thereof 中国科学院合肥物质科学研究院 2025-03-11 CN claimed
CN-119352160-A Rare earth doped yttrium gallate laser material and preparation method and application thereof 中国科学院合肥物质科学研究院 2025-01-24 CN claimed
EP-3367890-B1 A PHOTOACTIVATABLE DRUG FOR USE IN RADIOTHERAPY IMMUNOLIGHT LLC (US) 2024-12-04 EP claimed
US-11981846-B2 Nanocomposite and uses thereof ACADEMIA SINICA (TW) 2024-05-14 US claimed
US-11786595-B2 Methods for radiotherapy to trigger light activation drugs IMMUNOLIGHT, LLC (US) 2023-10-17 US claimed
US-20230109074-A1 NON-INVASIVE SYSTEMS AND METHODS FOR SELECTIVE ACTIVATION OF PHOTOREACTIVE RESPONSES IMMUNOLIGHT, LLC (US) 2023-04-06 US claimed
US-11534622-B2 Non-invasive systems and methods for selective activation of photoreactive responses IMMUNOLIGHT, LLC (US) 2022-12-27 US claimed
US-20220257524-A1 NANOCOMPOSITE PARTICLE AND USES THEREOF ACADEMIA SINICA (TW) 2022-08-18 US claimed
WO-2008130562-A1 COMPOSITIONS COMPRISING ORGANIC AND INORGANIC PHOSPHORS FOR CONVERTING ELECTROMAGNETIC RADIATION AND METHODS FOR USING THE SAME BERNSTEIN ERIC F (US) 2008-10-30 WO claimed
US-20060269483-A1 SEM cathodoluminescent imaging using up-converting nanophosphors THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2006-11-30 US claimed
WO-2006093966-A2 SEM CATHODOLUMINESCENT IMAGING USING UP-CONVERTING NANOPHOSPHORS THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2006-09-08 WO claimed
WO-2006017140-A2 METHODS FOR OPTICALLY ENCODING AN OBJECT WITH UPCONVERTING MATERIALS AND COMPOSITIONS USED THEREIN PARALLEL SYNTHESIS TECHNOLOGIES, INC. (US) 2006-02-16 WO claimed
US-20050136486-A1 Upconverting phosphors for use as signaling entities conjugated on optically encoded objects; optical barcodes PARALLEL SYNTHESIS TECHNOLOGIES, INC. 2005-06-23 US claimed
US-20030207331-A1 Encoding methods using up-converting phosphors for high-throughput screening of catalysts SRI INTERNATIONAL 2003-11-06 US claimed
US-6537829-B1 Phosphorescent, fluorescent labels; detectable labels, bioassays for detecting soluble, suspended, particulate substances; use in performing sensitive detection of analytes, such as biological macromolecules SRI INTERNATIONAL 2003-03-25 US claimed
US-6399397-B1 TRANSPORTATING, CAPTURING LIQUID SAMPLE, LABELING WITH PHOSPHORS SRI INTERNATIONAL 2002-06-04 US claimed
US-20020045190-A1 Encoding methods using up-converting phosphors for high-throughput screening of catalysts SRI INTERNATIONAL 2002-04-18 US claimed
WO-2002004527-A2 ENCODING METHODS USING UP-CONVERTING PHOSPHORS FOR HIGH-THROUGHPUT SCREENING OF CATALYSTS SRI INTERNATIONAL (US) 2002-01-17 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11786595-B2 Methods for radiotherapy to trigger light activation drugs MTNR1A, ATM, CHUK KDM4E 3214/4885LMNA 2361/4885TDP1 264/4885
US-12539278-B2 Nanocomposite particle and uses thereof SGMS2, SGMS1, PHOSPHO1 KDM4E 2456/4885LMNA 2298/4885TDP1 3763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.